(Reuters) – The U.S. Food and Drug Administration (FDA) will not make a decision on Bristol Myers Squibb and 2seventy bio’s marketing application of their blood cancer therapy, Abecma, for earlier lines of treatment by Dec. 16.
The health regulator will hold a meeting of external experts before a decision, the companies said on Monday.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj Kalluvila)
